糖尿病视网膜前膜中巨噬细胞相关促纤维化程序及法瑞西单抗的调控作用
研究分析糖尿病患者视网膜前膜(ERM)中巨噬细胞浸润及促纤维化程序,并用法瑞西单抗处理体外巨噬细胞,发现糖尿病ERM中Tie2阳性巨噬细胞增多,法瑞西单抗浓度依赖性抑制促纤维化基因表达。
要点
- 糖尿病视网膜病变患者的ERM中巨噬细胞浸润增加,Tie2阳性巨噬细胞富集。
- 法瑞西单抗浓度依赖性抑制巨噬细胞TGF-β1等促纤维化基因表达。
- 法瑞西单抗下调ACTA2、纤连蛋白、MMP2、MMP9等纤维化及细胞外基质相关基因。
核心结论
- 巨噬细胞相关促纤维化程序与糖尿病视网膜疾病中ERM形成相关。
- 法瑞西单抗可调节巨噬细胞极化和纤维化基因表达,为双靶点抑制Ang2和VEGFA的抗纤维化效应提供潜在生物学依据。
研究设计与样本
- 对人玻璃体切除术中获取的ERM标本进行免疫组化分析,评估巨噬细胞浸润及Tie2表达亚群。
- 使用PMA刺激的THP-1来源巨噬细胞,用法瑞西单抗处理后进行定量实时PCR分析炎症、促纤维化和细胞外基质相关基因。
- 分析公开的人纤维血管膜转录组数据集,检查纤维化相关基因程序的协同激活。
主要发现
- 与无糖尿病ERM相比,糖尿病视网膜病变患者的ERM显示巨噬细胞浸润增加和Tie2表达巨噬细胞富集。
- 体外PMA诱导巨噬细胞分化显著上调TGF-β1、IL-10、IL-1RN和CD163等炎症和促纤维化介质。
- 法瑞西单抗浓度依赖性减弱上述基因表达,对TGF-β1的抑制尤为显著。
- 法瑞西单抗还降低ACTA2、纤连蛋白、MMP2和MMP9等促纤维化和细胞外基质相关基因的表达。
- 转录组分析显示纤维血管膜中纤维化相关基因网络协同上调,ACTA2表达增加。
临床怎么用
- 提示巨噬细胞相关促纤维化程序可能是糖尿病ERM形成的机制之一。
- 法瑞西单抗对巨噬细胞极化和纤维化基因表达的调节作用,为双靶点抑制Ang2和VEGFA的抗纤维化效应提供潜在生物学背景。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Epiretinal membrane (ERM) formation in diabetic retinal disease is frequently associated with inflammation and fibrosis; however, the underlying cellular mechanisms remain incompletely defined. We investigated whether macrophage-associated profibrotic programs contribute to diabetic ERM formation and whether these pathways are modulated by faricimab, a dual angiopoietin-2 (Ang2) and vascular endothelial growth factor A (VEGFA) inhibitor. METHODS: Human ERM specimens obtained during vitrectomy were analyzed by immunohistochemistry to assess macrophage infiltration, including Tie2-expressing subsets. Macrophage-associated inflammatory and profibrotic responses were evaluated using PMA-stimulated THP-1-derived macrophages treated with faricimab, followed by quantitative real-time PCR analysis of inflammatory, profibrotic, and extracellular matrix-related genes. Publicly available transcriptomic datasets from human fibrovascular membranes were analyzed to examine coordinated activation of fibrosis-related gene programs. RESULTS: ERMs from patients with diabetic retinopathy (DR) demonstrated increased macrophage infiltration and enrichment of Tie2-expressing macrophages compared with non-diabetic ERMs. In vitro, PMA-induced macrophage differentiation markedly upregulated inflammatory and profibrotic mediators, including TGF-β1, IL-10, IL-1RN, and CD163. Faricimab attenuated the expression of these genes in a concentration-dependent manner, with particularly prominent suppression of TGF-β1. Faricimab also reduced the expression of profibrotic and extracellular matrix-related genes, including ACTA2, fibronectin, MMP2, and MMP9. Transcriptomic analyses revealed coordinated upregulation of fibrosis-related gene networks and increased ACTA2 expression in fibrovascular membranes. CONCLUSIONS: Macrophage-associated profibrotic programs are associated with ERM formation in diabetic retinal diseases. Faricimab modulates macrophage polarization and fibrotic gene expression, providing a potential biological context for the observed antifibrotic effects of dual Ang2 and VEGFA inhibition.
引用
- Lee SY, Kim DE, Kim A, et al. Macrophage-Associated Profibrotic Programs in Diabetic Epiretinal Membrane and Their Modulation by Faricimab. Invest Ophthalmol Vis Sci. 2026. PMID: 42910809. doi:10.1167/iovs.67.12.51
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。